
under the aegis of
**Mumbai Hematology Group**

**Thursday, 3rd December 2026**

# Panel discussion

## Subject 1: 05.45 pm (IST) onwards

## The role of Asciminib in early-line CML



### Dr. M. B. Agarwal

Prof & Head
Dept of Hematology Bombay Hospital
Institute of Medical Sciences
Mumbai

**Moderator**

## Subject 2: 06.30 pm (IST) (2.00 pm Italian time)

## Hereditary ineffective erythropoiesis in the genomic era: from genetic complexity to therapeutic perspectives



### Dr. Roberta Russo, PhD

Associate Professor of Medical Genetics
Dept. Molecular Medicine and Medical Biotechnology
University of Naples Federico II
Naples (Italy)

## Subject 3: 07.00 pm (IST) (02.30 pm Italian time)

## Updates on clinical and laboratory aspects of PIEZO1-related disorders



### Dr. I. Andolfo

Assistant Professor
Dept. Molecular Medicine and Medical Biotechnology
University of Naples Federico II
Naples (Italy)

www.mhgindia.com


Supported by:

Johnson&Johnson | NOVARTIS Reimagining medicine, together. | ADLEY ONCOLOGY

**Thursday, 3rd December 2026**

### Subject 4: 07.30 pm IST (3.00 pm Austria time)

## Current approach to AML treatment in Austria, Germany, and Switzerland, based on the Onkopedia guidelines focusing on frontline treatment




**Dr. Armin Zebisch**

Prof. Armin Zebisch
Division of Hematology
Medical university of Graz
Austria


### Subject 5: 08.30 pm IST (10.00 am Eastern time)

## Bispecific antibodies-based treatment of multiple myeloma




**Dr. Ajay K. Nooka, MD MPH**

Professor, Department of Hematology and Medical Oncology
Director, Myeloma Program
Associate Director of Clinical Research
Winship Cancer Institute
Emory University School of Medicine
Atlanta, USA

## Moderator



### Dr. M. B. Agarwal

Prof & Head
Dept of Hematology Bombay Hospital
Institute of Medical Sciences
Mumbai

## Panelists



### Dr Gopinathan M

Consultant Hematology & BMT
MGM Healthcare & Cancer Institute
Chennai



### Group Captain (Dr) Harshit Khurana

MBBS (AFMC), MD Medicine (AHRR),
DM Clinical Hematology (PGIMER),
PGD-HHM & PGD-MLS (Symbiosis)
Clinical Hematologist & BMT Physician
Professor and Senior Advisor (Medicine)
Army Hospital (Research and Referral),
Delhi Cantonment, New Delhi



### Dr. Priyanka Samal,

M.D, D.M (Clin. Hemat.)
Professor & Head
Dept. Of Clinical Hematology,
Hemato-oncology & Stem Cell Transplant
IMS & SUM Hospital
Bhubaneswar

## Guest Speaker




### Dr. Roberta Russo, PhD

Associate Professor of Medical Genetics
Dept. Molecular Medicine and Medical Biotechnology
University of Naples Federico II
Naples (Italy)


**She operates as a specialized medical geneticist and researcher at the CEINGE Biotecnologie Avanzate Franco Salvatore.**

**Her key clinical and research pillars include:**

- Rare Hereditary Anemias: Comprehensive molecular analysis of conditions such as Congenital Dyserythropoietic Anemias (CDA), Hereditary Spherocytosis, Hereditary Elliptocytosis, and Hereditary Stomatocytosis.

- Gene Discovery & Regulation: Identifying new causative genes and investigating specific regulatory mechanisms (such as GATA1 regulation of SEC23B expression in CDA type II).

- Next-Generation Sequencing (NGS): Implementing paradigm-shifting genomic mutational screenings for bone marrow failure and red blood cell defects.

## Guest Speaker




### Dr. I. Andolfo

Assistant Professor
Dept. Molecular Medicine and Medical Biotechnology
University of Naples Federico II
Naples (Italy)


### Research Focus

- Hereditary Anemias: Molecular genetics and pathophysiology of rare anemias, including congenital dyserythropoietic anemias and dehydrated hereditary stomatocytosis.
- Red Blood Cell Membrane & Iron Metabolism: Study of membrane defects and iron homeostasis, including the role of PIEZO1.
- Genetics & Molecular Diagnostics: Development of multi-gene panel testing and targeted next-generation sequencing (t-NGographic/NGS) for diagnosing hereditary disorders

## Guest Speaker



### Dr. Armin Zebisch

Prof. Armin Zebisch
Division of Hematology
Medical university of Graz
Austria

- He is a prominent Austrian physician and researcher specializing in hematology and experimental oncology.
- He serves as a leading faculty member and physician within the Clinical Division of Hematology at the Medical University of Graz in Austria.
- Head of the Research Unit: Signal Transduction in Myeloid Malignancies at the Otto Loewi Research Center (Division of Pharmacology). He leads a highly active translational research group—Team Zebisch—focused on the intersection of inflammation, autoimmunity, and hematologic cancers. The primary areas of work include Myeloid Leukemias, RAS-Oncogenes and Leukemia Biobanking.
- Graduated with his medical degrees from the Medical University of Graz.

## Guest Speaker



### Dr. Ajay K. Nooka, MD MPH

**Professor, Department of Hematology and Medical Oncology**
**Director, Myeloma Program**
**Associate Director of Clinical Research**
**Winship Cancer Institute**
**Emory University School of Medicine**
**Atlanta, USA**

- Dr. Ajay K. Nooka, MD, MPH, FACP, is a board certified hematologist specializing in the treatment of patients with multiple myeloma and plasma cell disorders.
- Dr. Nooka serves as associate director of clinical research for Winship Cancer Institute of Emory University.
- In this role, he provides strategic oversight for all clinical research conducted at Winship, with a focus on supporting high-quality, safe and ethical research and ensuring that patients have equitable access to Winship's innovative clinical trials.
- He also serves as scientific director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University
- As director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
- Dr. Nooka is a clinical member of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University.
- He serves on the steering committee of the Multiple Myeloma Research Consortium.

## Scientific Agenda

Welcome note and introduction of guest speaker
**Dr. M. B. Agarwal, Mumbai**

Panel discussion

| | |
|---|---|
| **Subject 1:** | **The role of Asciminib in early-line CML** |
| **Moderator:** | **Dr. M. B. Agarwal, Mumbai** |
| **Panelists** | **Dr. Gopinathan M, Chennai**<br>**Dr. Harshit Khurana, Delhi**<br>**Dr. Priyanka Samal, Bhubaneswar** |

Guest lectures

| | |
|---|---|
| **Subject 2:** | **Hereditary ineffective erythropoiesis in the genomic era: from genetic complexity to therapeutic perspectives** |
| **Speaker:** | **Dr. Roberta Russo, Italy** |
| **Subject 3:** | **Updates on clinical and laboratory aspects of PIEZO1-related disorders** |
| **Speaker:** | **Dr. I. Andolfo, Italy** |
| **Subject 4:** | **Current approach to AML treatment in Austria, Germany, and Switzerland, based on the Onkopedia guidelines focusing on frontline treatment** |
| **Speaker:** | **Dr. Armin Zebisch, Austria** |
| **Subject 5:** | **Bispecific antibodies-based treatment of multiple myeloma** |
| **Speaker:** | **Dr. Ajay Nooka, USA** |

Interactive session with Indian discussants

| | |
|---|---|
| **Moderator:** | **Dr. M. B. Agarwal, Mumbai** |
| **Vote of thanks** | **Dr. M. B. Agarwal, Mumbai** |

## Registration Link

**Click on below link to register:**

***https://forms.gle/h1A3WYCbvCWL23Ym7***

All registered delegates will receive the attendee joining link on your registered email id. You may also visit our website www.mhgindia.com

Please send your queries related to the webinar on kalpesh@perfectsquare.co.in.

---

under the aegis of
**Mumbai Hematology Group**

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road,
Dadar TT, Mumbai 400014.
Email ID: mbagarwal1@gmail.com

---

Supported by:

Johnson&Johnson | NOVARTIS Reimagining medicine, together. | ADLEY ONCOLOGY

---

Event Partner:

PERFECT SQUARE
www.perfectsquare.co.in